Expanding treatment options for cancer patients.

Celcuity diagnoses cancer drivers molecular tests cannot detect to identify new treatment options for patients.

Cancer patients need more options.

  • Genomic testing cannot identify the driver of all patients’ cancer.
  • Without knowing the driver, doctors cannot prescribe many targeted therapies.
  • CELsignia fills this void by measuring complex cellular activities genomic tests cannot detect.
  • Patients whose cancer driver is diagnosed by CELsignia have more treatment options.